NEUROENDOCRINE A021602
Study #A021602Randomized, Double-Blind Phase III Study of Cabozantinib Versus Placebo In Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Back To Clinical Trials NCI Database Entry
Randomized, Double-Blind Phase III Study of Cabozantinib Versus Placebo In Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Back To Clinical Trials NCI Database Entry